Reality bites: Lack of cash stops many Bathurst people seeing dentist | Western Advocate

news, local-news, news

A NEW study released this month has found up to 25 per cent of people aged 15 and over in Bathurst have delayed seeing a dental professional in the last 12 months due to concerns over the cost. The study, released by the NSW Council of Social Service, maps economic disadvantage across NSW. Australian Dental Association NSW president Dr Kathleen Matthew said delaying dental health treatments put people’s overall health at risk. Dr Matthew said it was “clearly concerning” one in four people are delaying dental treatment because they can’t afford it. “I think that’s a very important conversation to have with the population.” She said the flow on effects from not getting treatment include pain and dental stress which only gets worse, costs more money and requires higher intervention in the end. Dr Matthew also said the lower end of social economic scale are more vulnerable to dental disease with dental disease the most chronic disease there is in the community, worldwide. ALSO MAKING NEWS: “It’s (dental) the missing part of the health system … if you visit the GP it’s subsidised by the government if you get a script filled subsidised by the PBS.” Complicating the matter are the extensive wait lists for public dental services. “The waiting list for the public system is a two door system…. if you have dental pain or infection there is a triage system in place but that’s just to sort out that issue,” she explained. “If you have multiple issues, you’re on the waiting list which has a bench mark of six months, in Bathurst there are 7000 people waiting,” she said. Dr Matthews said the time had come to discuss the health system and ask does it actually work. “The mouth is part of the body but there is form of subsidy under Medicare (for dental treatment). “If you’ve got a diseased wisdom tooth and the competing priory is getting good on the table for your family, then that’s going to be the higher priority,” she said. “Dentists get criticised about their costs, but the reality is we are running a health business without government support,” she said. “The Government needs to sit down come up with a plan to treat those vulnerable to dental disease more effectively and efficiently.” Dr Matthews said there is child dental benefit scheme for low income families, who receive $1000 in dental treatment per child, but said more needs to be done. She said the government needs to look at the staged implementation of a universal scheme for basic dental care.

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/XnvAZ6uRSAiEC6kxxV6TdP/e195113f-d60a-4bad-b13d-95d035a1d554.jpg/r21_624_8237_5266_w1200_h678_fmax.jpg

HAVE YOUR SAY

Read more

Ways to cash in on regenerative medicine

Despite the ethical questions, the field of stem cell research has not slowed – particularly within the field of regenerative medicine where the potential for cellular regeneration to kickstart the body’s repair mechanism is huge.

But is it as simple as gathering stem cells, putting them into the human body and seeing how things go?

First let’s understand the balance within our bodies. Take for example bones, made up by the balance of two types of cell, osteoblasts (builders) and oesteoclasts (dissolvers).

If the body has excess osteoblasts it can lead to abnormal bone growth such as bunions through to Paget’s disease. And too many osteoclast cells can lead to bone degeneration conditions such as osteoporosis. Stem cells as the natural building blocks of the body could be used to tell the existing cells how they should be acting to get the balance back and avoid these issues.

While in principle this sounds good, when it comes to degenerative diseases such as Parkinson’s, multiple sclerosis, neurodegeneration and cancer, these are complex conditions where imbalances in cell development and chronic inflammation need a more detailed and complete “message” to resolve these issues.

In short, and in keeping with the theme of the US election, rather than rely on multiple random and chaotic tweets from the President, what is required is a more detailed email explaining what each cell should be doing to ensure a harmonious operating environment.

The email – exosomes

In the 1990’s researchers identified that exosomes that secrete naturally from cells were not nanoparcel debris as first thought. Rather, exosomes are bioactive and have the specialised function of carrying messages to other cells in the body instructing them on how they should act.

So if exosomes could be harvested and then delivered to the specific area of the body that needs them, they could aid the body’s healing process.

Excitingly there is a listed Australian company at the forefront of this field of work. Exopharm is the owner of proprietary manufacturing technology called LEAP, which performs the exosome extraction and purification process.

The technology created by the company’s chief executive, Ian Dixon, is designed to complete the purification process and facilitate the mass production of pharmaceutical-grade exosomes.

The company has candidates in testing and development, ranging from wound healing to curing dry age-related macular degeneration. Further, it recently signed exclusive IP agreements for the delivery of engineered extracellular vesicles (EEV) which can be designed to carry specific cargos to target particular cells or tissue to cure illnesses.

From an investment perspective, the exciting thing that Exopharm offers is the potential for numerous products to be commercialised using its manufacturing process. It will seek licensing arrangements and partnerships with other parties to deliver their drugs at scale using Exopharm technology

Dixon is supported by a team with experience from big pharma, including Alison Mew, previously a senior manager at CSL and now director of manufacturing and development at Exopharm.

While all biotech firms at the pre-revenue stages carry risks, specifically

Read more

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020

  • Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of type 2 diabetes in July 2020 and a target launch is expected in fiscal year 20211; a milestone payment of EUR 4 million was received in Q3 2020 from Sumitomo Dainippon Pharma

  • Imeglimin Phase 3 TIMES results were presented at the 56th European Association for the Study of Diabetes (EASD) meeting; Phase 2b, Phase 3 TIMES results, and additional safety data were presented at the 63rd Annual Meeting of Japanese Diabetes Society (JDS)

  • PXL770 Phase 2a trial for the treatment of NASH met its primary efficacy endpoint and trial objectives, and it was observed to be safe and well tolerated

  • PXL770 profile supports development in NASH and also further evaluation for combination use, as well as utility of adenosine monophosphate-activated protein kinase (AMPK) activation in other chronic and rare metabolic diseases

  • PXL065 Phase 2 trial was initiated in biopsy-proven NASH patients in September 2020; streamlined development with a single Phase 2 trial given knowledge of pioglitazone, including data in NASH, and 505(b)(2) regulatory pathway, which offers the opportunity for an efficient and lower risk development program

  • As of September 30, 2020, cash and cash equivalents were EUR 41.5 million (USD 48.6 million)

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2020.

“During the third quarter, we continued to make significant progress and accomplished a number of important clinical and corporate objectives, including reporting positive results from a Phase 2a proof-of-concept trial for PXL770, demonstrating its potential in NASH. These results are the first human clinical assessment of a direct AMPK activator and support longer-term evaluation of important histological endpoints, such as inflammation and fibrosis, and exploring subpopulations for further differentiation. The data also demonstrate that AMPK activation may lead to broader utility for the treatment of other chronic and rare metabolic diseases. In addition, we initiated a streamlined Phase 2 trial for PXL065 in NASH and strengthened our cash position with non-dilutive funding from a milestone payment of EUR 4 million for the Imeglimin New Drug Application (NDA) submission in Japan and the recent PGE loan of EUR 6 million from the French government,” said Thomas Kuhn, CEO of Poxel.

“For the remainder of this year, we expect several upcoming milestones and events including finalization of the PXL770 Phase 2b clinical trial design, presentations for PXL770 and PXL065 at several scientific meetings as well as publishing results in peer-reviewed scientific journals and additional preclinical data related to our AMPK and deuterated-TZD platforms. Furthermore, our partner, Metavant, is in discussions with the U.S. Food and Drug Administration (FDA) regarding the Imeglimin Phase 3 program in type 2 diabetes patients with chronic kidney disease (CKD) stages 3b/4,” added Thomas Kuhn,

Read more